SHARE

As per the report published by Fior Markets, the global sexually transmitted diseases (STD) treatment market is expected to grow from USD 35.20 billion in 2018 to USD 84.81 billion by 2026 at a CAGR of 11.54% during the forecast period 2019-2026. North America is the leading region of the market due to the factors including increasing government initiative for disease awareness and implementation of prenatal screening programs, presence of major players, and rapid technological advancements.

DOWNLOAD FREE SAMPLE REPORT:https://www.fiormarkets.com/report-detail/399166/request-sample

Sexually Transmitted Diseases (STD) Treatment Market by Disease Type (Chlamydia, Syphilis, Herpes Simplex Virus, HBV, HIV, Other), Therapy Type, Testing Devices, Route of Administration, Distribution Channels, Region and Global Forecast 2019-2026.

Prominent companies in the industry include Merck & Co. Inc., Pfizer Inc, GlaxoSmithKline Plc, F. Hoffmann-La Roche AG, Gilead Sciences Inc., AbbVie Inc., Johnson & Johnson, Bristol-Myers Squibb, Eli Lilly and Company, Abbott Laboratories, Hologic, Inc., Cepheid Inc., DiaSorin Inc., Becton Dickinson And Company, and others.The Merck & Co. Inc., Pfizer Inc, GlaxoSmithKline,Abbott, and Hologic are the top leading players in the globalsexually transmitted diseases (STD) treatment market. In order to their enhance market position, the key players are now focusing on adopting the strategies such as product innovations, mergers & acquisitions, recent developments, joint venture, collaborations, and partnership. For instance, in 2018, Inovio Pharmaceuticals, Inc. signed an agreement with ApolloBio Corp. for the exclusive rights for development, manufacturing, and commercialization of VGX – 3s100, Inovio’s DNA immunotherapy product. This product is used for pre-cancer indication.

The sexually transmitted diseases (STD) treatment market is segmented on the basis of disease type, therapy type, testing devices, route of administration, and distribution channels.Disease type segment includes gonorrhea, chlamydia, syphilis, herpes simplex virus, hepatitis B virus (HBV), human immunodeficiency virus (HIV), and other. The chlamydia segment registered the largest market share of 22.04% in the year 2018 due to the increasing cases of chlamydia globally and growing rate of chlamydia screening.Therapy type segment covers anti-bacterial drugs, anti-viral drugs, and anti-fungal drugs. The anti-bacterial drugs segment is anticipated to grow with the highest CAGR 12.82% during the forecast period. The moderately priced drug and increasing consumption of anti-bacterial drugs to treat certain kinds of bacterial infections has increased the anti-bacterial drugs segment size. Testing devices segment is divided into instruments & systems and diagnostic kits.The instruments & systems segment is further divided into PCR, Immunochromatographic assays, flow cytometers, differential light scattering machines, and enzyme linked immunosorbent assay (ELISA). The diagnostic kits segment further covers phone chips (microfluidics + ICT) and portable / bench top / rapid diagnostic kits. The instruments & systems segment valued around USD 18.53 billion in 2018 due to its increased use in hospitals and clinics in the STD treatments. Route of administration segment is categorized into oral, topical, injectable. The oral segment is anticipated to hold the highest market share of 34.49% over the forecast period owing to ease of consuming orally and painless treatment method. The oral intake of the medicines are much preferred as they can be swallowed, chewed, or placed under tongue to dissolve.Distribution channels segment consists of hospital pharmacies, retail pharmacies, and online pharmacies. The online pharmacies segment accounted the highest market share of 35.39% in 2018 and is expected to dominate the market during the forecast period. This was attributed to the fact that online pharmacies are becoming a wider supply chain than hospitals and retail pharmacies.


BROWSE COMPLETE REPORT AND TABLE OF CONTENTS:https://www.fiormarkets.com/report/sexually-transmitted-diseases-std-treatment-market-by-disease-399167.html

The sexually transmitted diseases (STDs) represents to a various clinical syndromes and infections initiated by pathogens that are developed and spread through the sexual activity. Increasing occurrence of sexually transmitted diseases, implementation of national screening programs, and supporting reimbursement for sexually transmitted diseases (STD) testing are the key driving factors for the sexually transmitted diseases (STD) treatment market. The low rate of detection for diseases due to social stigma and huge proportion of patients infected with STDs in out-of-reach geographic areas may limit the growth of the market. However, increasing governmental initiatives to spread awareness through organization of campaigns, free diagnostic camps and niche opportunities for technology & POC test providers in emerging economies is expected to boost the sexually transmitted diseases (STD) treatment market over the forecast period.


Customization of the Report:This report can be customized to meet the client’s requirements. Please connect with our sales team (sales@fiormarkets.com), who will ensure that you get a report that suits your needs.